ResearcherInsermActive in the last 2 years
Fabrice Raineri
Matched on ORCID iD 0000-0001-9878-3434; OpenAlex author ID A5012507338. Sources: OpenAlex.
Their work
- Papers
- 2
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2025: 2 papers
Papers 2
- The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pancreatic ductal adenocarcinoma therapy. Co-author DOI 10.1016/j.ejphar.2025.177310↗
- Corrigendum to "The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pancreatic ductal adenocarc… Co-author DOI 10.1016/j.ejphar.2025.177383↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Sabrina Belbekhouche · 2 shared papers, 2025 · strength 0.47
- Paper The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pan… DOI 10.1016/j.ejphar.2025.177310↗
- Paper Corrigendum to "The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic … DOI 10.1016/j.ejphar.2025.177383↗
- Benedetta Ferrara · 2 shared papers, 2025 · strength 0.47
- Paper The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pan… DOI 10.1016/j.ejphar.2025.177310↗
- Paper Corrigendum to "The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic … DOI 10.1016/j.ejphar.2025.177383↗
- José Laurent Cohen · 2 shared papers, 2025 · strength 0.47
- Paper The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pan… DOI 10.1016/j.ejphar.2025.177310↗
- Paper Corrigendum to "The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic … DOI 10.1016/j.ejphar.2025.177383↗
- Ilaria Cascone · 2 shared papers, 2025 · strength 0.47
- Paper The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pan… DOI 10.1016/j.ejphar.2025.177310↗
- Paper Corrigendum to "The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic … DOI 10.1016/j.ejphar.2025.177383↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.